Personalized Medicine Bioinformatics Market Report 2025

The personalized medicine bioinformatics market size has grown rapidly in recent years. It will grow from $3.4 billion in 2024 to $3.87 billion in 2025 at a compound annual growth rate (CAGR) of 13.7%. The growth during the historic period was driven by the increasing adoption of genomic sequencing technologies, rising demand for targeted therapies, expansion of bioinformatics software solutions, progress in research and development within personalized medicine, and regulatory support for precision medicine initiatives.

The personalized medicine bioinformatics market size is expected to see rapid growth in the next few years. It will grow to $6.4 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth during the forecast period is fueled by the integration of artificial intelligence and machine learning, greater use of real world data and predictive analytics, expansion of cloud based bioinformatics platforms, rising collaborations between healthcare and technology companies, and a growing focus on patient centric treatment approaches. The primary trends in the forecast period include the development of predictive analytics tools, innovations in multi omics integration, adoption of real time patient monitoring systems, advances in genome editing technologies, and the expansion of patient centric healthcare models.

The growing demand for personalized medicine is expected to drive the expansion of the personalized medicine bioinformatics market. Personalized medicine customizes prevention, diagnosis, and treatment based on an individual’s unique genetic profile, health status, and lifestyle factors. The rise of personalized medicine is fueled by advancements in genomic profiling and data analytics, which enable more accurate genetic assessments, leading to more targeted treatments and improved outcomes while reducing the need for trial-and-error approaches. Personalized medicine bioinformatics processes genomic and clinical data to provide insights into individual health conditions, facilitating precise treatment decisions and predicting drug responses. This also guides the use of targeted therapies that enhance personalized patient care. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized therapies for rare disease patients in 2023, a significant increase from just six in 2022. This surge in personalized treatments is contributing to the growth of the personalized medicine bioinformatics market.

Companies in the personalized medicine bioinformatics market are increasingly focused on developing advanced solutions such as predictive analytics platforms to improve disease prediction and enhance patient outcomes. Predictive analytics platforms use machine learning, algorithms, and statistical models to analyze both historical and real-time data, helping healthcare providers anticipate risks, refine treatments, and make proactive decisions. For instance, in April 2023, Certis Oncology Solutions, a US-based biotechnology company, introduced CertisAI, an AI/ML-driven predictive analytics platform. This platform uses big data, statistical algorithms, and machine learning to predict the efficacy of drugs based on gene expression biomarkers. Its goal is to speed up drug discovery and support the development of companion diagnostics in precision oncology. The platform is currently validating its approach to predicting therapeutic responses and is available as a service to biopharmaceutical companies to help make more informed decisions in early drug development and personalized cancer treatment.

In May 2025, GeneDx Holdings Corp., a US-based genomic testing and diagnostic services provider, acquired Fabric Genomics for up to $51 million. This acquisition aims to strengthen GeneDx’s capabilities in decentralized, AI-driven genomic interpretation, speeding up the delivery of scalable and rapid genomic diagnostics. Fabric Genomics specializes in AI-powered software and services for genomic interpretation, focusing on whole genome sequencing analysis for rare diseases, hereditary risks, and cancer testing.

Major players in the personalized medicine bioinformatics market are F. Hoffmann-La Roche AG, Merck KGaA Darmstadt Germany, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., Guardant Health Inc., Sophia Genetics SA, DNAnexus Inc., Deep Genomics Inc., Congenica Ltd, Phase Genomics Inc., Analome Inc., Pluto Bioinformatics Inc., BioBam Bioinformatics S.L., OncoBox Inc.

North America was the largest region in the personalized medicine bioinformatics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in personalized medicine bioinformatics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the personalized medicine bioinformatics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Personalized medicine bioinformatics refers to the application of advanced computational tools combined with biological data to analyze individual genetic and molecular profiles. It enables accurate interpretation of complex biological information to support informed medical decision making. Personalized medicine bioinformatics improves the precision of clinical insights and accelerates the identification of patient specific strategies. Its primary advantage lies in providing data driven clarity for understanding individual biological variability.

The primary technology types of personalized medicine bioinformatics include gene sequencing, pharmacogenomics, microarray technology, artificial intelligence based analytics platforms, and others. Gene sequencing determines the exact order of nucleotides in a DNA or RNA molecule to identify genetic variations that influence individual responses to drugs and therapies. It is applied in fields such as genomics, proteomics, transcriptomics, metabolomics, epigenomics, and others, and is utilized by diverse end users, including biotechnology and pharmaceutical companies, clinical diagnostic laboratories, hospitals and academic medical centers, contract research organizations, biobanks, and others.

The personalized medicine bioinformatics market research report is one of a series of new reports that provides personalized medicine bioinformatics market statistics, including personalized medicine bioinformatics industry global market size, regional shares, competitors with a personalized medicine bioinformatics market share, detailed personalized medicine bioinformatics market segments, market trends and opportunities, and any further data you may need to thrive in the personalized medicine bioinformatics industry. The personalized medicine bioinformatics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The personalized medicine bioinformatics market consists of revenues earned by entities by providing services next-generation sequencing (NGS), interpretation, variant annotation, and multi-omics data integration. The market value includes the value of related goods sold by the service provider or included within the service offering. The personalized medicine bioinformatics market also includes sales of genomic analysis software, variant interpretation and annotation tools, clinical decision support systems, and bioinformatics data management and workflow tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.